Table 1.

Demographic patient characteristics.

Characteristic N = 22	No. (%)
Median age (range), years	53 (36–71)
<63	17 (77%)
≥63	5 (23%)
Sex
Male	19 (86%)
Female	3 (14%)
ECOG performance status (range)	1–3
<2	17 (77%)
≥2	5 (23%)
AFP, (range) ng/ml	1–68,368
<40	10 (45%)
≥40	12 (55%)
HBV-DNA, (range) copies/ml	0–7,300
<215	15 (68%)
≥215	7 (32%)
Child-Pugh
A	13 (59%)
B	9 (41%)
Hepatectomy
Yes	8 (36%)
No	14 (64%)
TACE
Yes	11 (50%)
No	11 (50%)
Number of nivolumab cycles (range)	1–28
<9	13 (59%)
≥9	9 (41%)
Single dose of nivolumab, (range) mg	100–240
<200	3 (14%)
≥200	19 (86%)
Combined treatment
Targeted therapy	15 (68%)
Chemotherapy	7 (32%)